Nimotop S (Nimodipine)

Nimodipine, the active ingredient in Nimotop S, is a calcium channel blocker (dihydropyridine) presented as an intravenous solution for intravenous use. It helps prevent cerebral vasospasm after subarachnoid hemorrhage in adult patients. GNH USA supplies Nimotop S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine acts on cerebral vascular smooth muscle to reduce the risk of vasospasm after subarachnoid hemorrhage. - Subarachnoid hemorrhage: prevention of cerebral vasospasm, reducing delayed ischemic neurological deficits. - Aneurysmal SAH: lowers incidence of secondary cerebral ischemia. - Neurocritical care: adjunct to standard therapy for managing post‑hemorrhagic complications.

Nimotop S may cause a range of adverse reactions.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Headache: mild to moderate intensity. - Flushing: warmth and redness of skin. - Nausea: occasional upset stomach. - Dizziness: sensation of light‑headedness. - Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure decline requiring intervention. - Myocardial infarction: rare cardiac ischemic events. - Arrhythmias: abnormal heart rhythms. - Anaphylactic reaction: severe allergic response. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before using Nimotop S, clinicians should consider several safety measures. - Blood pressure monitoring: watch for hypotension during infusion. - Cardiac disease: use cautiously in patients with existing heart conditions. - Infusion rate: avoid rapid administration to reduce cardiovascular stress. - Hepatic function: assess liver status, especially in patients with known impairment. - Hypersensitivity: contraindicated in individuals with known allergy to nimodipine or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nimotop S can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma nimodipine levels. - Other calcium‑channel blockers: additive vasodilatory effect leading to cardiovascular instability.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic concentration. - Beta‑blockers: combined effect can enhance bradycardia. - Diuretics: may potentiate hypotensive response.